Theravance Biopharma Inc

0TB

Company Profile

  • Business description

    Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

  • Contact

    901 Gateway Boulevard
    South San FranciscoCA94080
    USA

    T: +1 650 808-6000

    E: [email protected]

    https://www.theravance.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    97

Stocks News & Analysis

stocks

Overvalued ASX mining giant

Solid start to 2026 but shares overvalued.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

With recent structural changes and strong Azure performance, here’s what we think of Microsoft stock.
stocks

Tesla earnings: Shares fall as market focuses on uncertainty in near term

Are shares overpriced despite the fall?

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,317.2026.50-0.28%
CAC 408,225.630.15-0.00%
DAX 4024,239.8932.100.13%
Dow JONES (US)47,207.12472.511.01%
FTSE 1009,645.6267.050.70%
HKSE26,160.15192.170.74%
NASDAQ23,204.87263.071.15%
Nikkei 22549,299.65658.041.35%
NZX 50 Index13,391.5914.490.11%
S&P 5006,791.6953.250.79%
S&P/ASX 2009,019.0025.20-0.28%
SSE Composite Index3,950.3127.900.71%

Market Movers